Effect of proteinase inhibitor Camostat Mesilate on nephrotic syndrome with diabetic nephropathy

T. Onbe; H. Makino; I. Kumagai; T. Haramoto; K. Murakami; Z. Ota

doi:10.1016/0891-6632(91)90060-3

Effect of proteinase inhibitor Camostat Mesilate on nephrotic syndrome with diabetic nephropathy

T. Onbe, H. Makino, I. Kumagai, T. Haramoto, K. Murakami, Z. Ota

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Abstract

The effect of serine protease inhibitor Camostat Mesilate on nephrotic syndrome with diabetic nephropathy was evaluated. Eight patients with nephrotic syndrome associated with diabetic nephropathy were orally administered 600 mg of Camostat Mesilate per day. Three patients showed a reduction of urinary protein excretion promptly at 4 weeks. Serum protein and degree of edema improved significantly at 4 weeks. Camostat Mesilate had no effect on renal function assessed by creatinine clearance. During the observation period there were no significant changes in blood pressure, level of blood sugar, or HbA₁c. Camostat Mesilate would be beneficial for the treatment of diabetic nephropathy.

Original language	English
Pages (from-to)	167-168
Number of pages	2
Journal	Journal of Diabetic Complications
Volume	5
Issue number	2-3
DOIs	https://doi.org/10.1016/0891-6632(91)90060-3
Publication status	Published - Jan 1 1991

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism
Endocrinology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/0891-6632(91)90060-3

Cite this

@article{b013a32db6b648f29531e3290961ee8d,

title = "Effect of proteinase inhibitor Camostat Mesilate on nephrotic syndrome with diabetic nephropathy",

abstract = "The effect of serine protease inhibitor Camostat Mesilate on nephrotic syndrome with diabetic nephropathy was evaluated. Eight patients with nephrotic syndrome associated with diabetic nephropathy were orally administered 600 mg of Camostat Mesilate per day. Three patients showed a reduction of urinary protein excretion promptly at 4 weeks. Serum protein and degree of edema improved significantly at 4 weeks. Camostat Mesilate had no effect on renal function assessed by creatinine clearance. During the observation period there were no significant changes in blood pressure, level of blood sugar, or HbA1c. Camostat Mesilate would be beneficial for the treatment of diabetic nephropathy.",

author = "T. Onbe and H. Makino and I. Kumagai and T. Haramoto and K. Murakami and Z. Ota",

year = "1991",

month = jan,

day = "1",

doi = "10.1016/0891-6632(91)90060-3",

language = "English",

volume = "5",

pages = "167--168",

journal = "Journal of Diabetes and its Complications",

issn = "1056-8727",

publisher = "Elsevier Inc.",

number = "2-3",

}

TY - JOUR

T1 - Effect of proteinase inhibitor Camostat Mesilate on nephrotic syndrome with diabetic nephropathy

AU - Onbe, T.

AU - Makino, H.

AU - Kumagai, I.

AU - Haramoto, T.

AU - Murakami, K.

AU - Ota, Z.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - The effect of serine protease inhibitor Camostat Mesilate on nephrotic syndrome with diabetic nephropathy was evaluated. Eight patients with nephrotic syndrome associated with diabetic nephropathy were orally administered 600 mg of Camostat Mesilate per day. Three patients showed a reduction of urinary protein excretion promptly at 4 weeks. Serum protein and degree of edema improved significantly at 4 weeks. Camostat Mesilate had no effect on renal function assessed by creatinine clearance. During the observation period there were no significant changes in blood pressure, level of blood sugar, or HbA1c. Camostat Mesilate would be beneficial for the treatment of diabetic nephropathy.

AB - The effect of serine protease inhibitor Camostat Mesilate on nephrotic syndrome with diabetic nephropathy was evaluated. Eight patients with nephrotic syndrome associated with diabetic nephropathy were orally administered 600 mg of Camostat Mesilate per day. Three patients showed a reduction of urinary protein excretion promptly at 4 weeks. Serum protein and degree of edema improved significantly at 4 weeks. Camostat Mesilate had no effect on renal function assessed by creatinine clearance. During the observation period there were no significant changes in blood pressure, level of blood sugar, or HbA1c. Camostat Mesilate would be beneficial for the treatment of diabetic nephropathy.

UR - http://www.scopus.com/inward/record.url?scp=0025950228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025950228&partnerID=8YFLogxK

U2 - 10.1016/0891-6632(91)90060-3

DO - 10.1016/0891-6632(91)90060-3

M3 - Article

C2 - 1770033

AN - SCOPUS:0025950228

SN - 1056-8727

VL - 5

SP - 167

EP - 168

JO - Journal of Diabetes and its Complications

JF - Journal of Diabetes and its Complications

IS - 2-3

ER -

Effect of proteinase inhibitor Camostat Mesilate on nephrotic syndrome with diabetic nephropathy

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this